Incidence of Primary Cancers and Intracranial Tumour Recurrences in Growth Hormone-Treated and Untreated Adult Hypopituitary Patients: Analyses from HypoCCS.
Research output: Contribution to journal › Article
Speculation remains that growth hormone (GH) treatment is associated with increased neoplasia risk. Studies in GH-treated childhood cancer survivors suggested higher rates of second neoplasms, while cancer risk data for GH-treated and untreated hypopituitary adults have been variable. We present primary cancer risk data from the Hypopituitary Control and Complications Study (HypoCCS) with a focus on specific cancers, and assessment of recurrence rates for pituitary adenoma (PA) and craniopharyngioma (CP).
|Research areas and keywords||
Subject classification (UKÄ) – MANDATORY
|Journal||European Journal of Endocrinology|
|Publication status||Published - 2015|